GENOWAY SA (ALGEN.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
ALGEN.PA Key Statistics, Chart & Performance
The current stock price of ALGEN.PA is 2.53 EUR. In the past month the price decreased by -0.78%. In the past year, price decreased by -35.13%.
ALGEN.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 66.13 | 43.32B | ||
| ARGX.BR | ARGENX SE | 65.51 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.74B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| NANO.PA | NANOBIOTIX | N/A | 841.84M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 779.35M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About ALGEN.PA
Company Profile
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
Company Info
GENOWAY SA
Technopark 2, 31 Rue Saint Jean-de-Dieu
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 128
Phone: 33437654100
GENOWAY SA / ALGEN.PA FAQ
Can you describe the business of GENOWAY SA?
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
What is the stock price of GENOWAY SA today?
The current stock price of ALGEN.PA is 2.53 EUR. The price decreased by -0.39% in the last trading session.
Does ALGEN stock pay dividends?
ALGEN.PA does not pay a dividend.
What is the ChartMill rating of GENOWAY SA stock?
ALGEN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for ALGEN stock?
The PE ratio for GENOWAY SA (ALGEN.PA) is 12.05. This is based on the reported non-GAAP earnings per share of 0.21 and the current share price of 2.53 EUR.
What is the employee count for ALGEN stock?
GENOWAY SA (ALGEN.PA) currently has 128 employees.
ALGEN.PA Technical Analysis
ALGEN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA. ALGEN.PA has only an average score on both its financial health and profitability.
ALGEN.PA Financial Highlights
Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.21. The EPS increased by 18.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.86% | ||
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| Debt/Equity | 0.26 |
ALGEN.PA Forecast & Estimates
9 analysts have analysed ALGEN.PA and the average price target is 6.02 EUR. This implies a price increase of 137.87% is expected in the next year compared to the current price of 2.53.
For the next year, analysts expect an EPS growth of -100% and a revenue growth -7.14% for ALGEN.PA